Developing Nucleic Acid Therapeutics
Developing Nucleic Acid Therapeutics
批准号:
6669938
负责人:
Alan M Gewirtz
金额:
$28.21万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2008-07-31
关键词:
SCID mouse affinity chromatography antineoplastics antisense nucleic acid biotechnology blood chemistry clinical research clinical trial phase I drug delivery systems drug design /synthesis /production drug screening /evaluation gene delivery system gene expression gene induction /repression gene targeting gene therapy human therapy evaluation leukemia mass spectrometry messenger RNA neoplasm /cancer therapy nucleic acid hybridization nucleic acid sequence oligonucleotides pharmacokinetics urinalysis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The prospect of employing antisense nucleic acids (ASNA) for treating human malignancies remains tantalizing, but unrealized. We hypothesize that ASNA would make better drugs if fundamental problems related to mRNA target sequence selection, and molecule delivery, were solved. The goal of this project is to address these core issues in the following specific aims: Aim #1- Develop A Rational Method For Targeting ASNA- We have developed self-quenching reporter molecules (SQRM) that signal only after hybridization, and have used these probes to "map" hybridization accessible sites in mRNA. We will determine the in vivo utility of this strategy by mapping additional target mRNAs, and measuring the efficiency with which sequence directed ASNA inhibit gene expression in living cells. The hypothesis that naturally occurring intracellular proteins might enhance ASNA/mRNA hybridization will also be tested. Candidate proteins will be identified by function, and by using affinity chromatography, and mass spectrometry. Finally, the utility of DNA backbones with enhanced strand invasion properties, with or without proteins that facilitate hybridization, will also be explored; Aim #2- Test the Hypothesis that Gene Silencing Efficiency of Rationally Targeted ASNA Can be Enhanced by Backbone, Sequence, or Pendant Modifications- ASNA cleave mRNA by enzymatic activity engineered into the molecule, or by activating endogenous RNaseH. We will examine the ability of rationally targeted ASNA, synthesized with various backbone modifications, to cleave mRNA targets in vitro and in vivo. The ability of SQRM with pendants that can be photoactivated to detect, and kill, cells on the basis of target mRNA expression will also be examined; Aim #3. Examine the ability of rationally designed, activity optimized ASNA to detect, and kill, tumor cells in animal models of human leukemia- Pharmacodynamic studies of optimized molecules will be undertaken, and their ability to serve as diagnostic, and therapeutic molecules in animal models of human leukemia will be explored.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing Nucleic Acid Therapeutics
-
批准号:6781865
-
项目类别:
-
资助金额:$28.21万
-
财政年份:2003
-
负责人:Alan M Gewirtz
-
依托单位:
Developing Nucleic Acid Therapeutics
-
批准号:7098020
-
项目类别:
-
资助金额:$27.55万
-
财政年份:2003
-
负责人:Alan M Gewirtz
-
依托单位:
Developing Nucleic Acid Therapeutics
-
批准号:7227454
-
项目类别:
-
资助金额:$26.75万
-
财政年份:2003
-
负责人:Alan M Gewirtz
-
依托单位:
Developing Nucleic Acid Therapeutics
-
批准号:6933789
-
项目类别:
-
资助金额:$28.21万
-
财政年份:2003
-
负责人:Alan M Gewirtz
-
依托单位:
REGULATORY ROLE OF PROTO-ONCOGENES IN NORMAL AND MALIGNANT HEMATOPOIESIS
-
批准号:6641451
-
项目类别:
-
资助金额:$19.72万
-
财政年份:2002
-
负责人:Alan M Gewirtz
-
依托单位:
VAV ANTISENSE ODN--A NOVEL THERAPEUTIC FOR HUMAN LEUKEMIAS
-
批准号:6477408
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2001
-
负责人:Alan M Gewirtz
-
依托单位:
REGULATORY ROLE OF PROTO-ONCOGENES IN NORMAL AND MALIGNANT HEMATOPOIESIS
-
批准号:6468899
-
项目类别:
-
资助金额:$19.72万
-
财政年份:2001
-
负责人:Alan M Gewirtz
-
依托单位:
CORE--STEM CELL FACILITY
-
批准号:6573835
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2001
-
负责人:Alan M Gewirtz
-
依托单位:
REGULATORY ROLE OF PROTO-ONCOGENES IN NORMAL AND MALIGNANT HEMATOPOIESIS
-
批准号:6334993
-
项目类别:
-
资助金额:$6.96万
-
财政年份:2000
-
负责人:Alan M Gewirtz
-
依托单位:
CORE--STEM CELL FACILITY
-
批准号:6454194
-
项目类别:
-
资助金额:$27.67万
-
财政年份:2000
-
负责人:Alan M Gewirtz
-
依托单位:
VAV ANTISENSE ODN--A NOVEL THERAPEUTIC FOR HUMAN LEUKEMIAS
-
批准号:6336433
-
项目类别:
-
资助金额:$21.6万
-
财政年份:2000
-
负责人:Alan M Gewirtz
-
依托单位:
CORE--STEM CELL FACILITY
-
批准号:6456218
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2000
-
负责人:Alan M Gewirtz
-
依托单位:
VAV ANTISENSE ODN--A NOVEL THERAPEUTIC FOR HUMAN LEUKEMIAS
-
批准号:6344746
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2000
-
负责人:Alan M Gewirtz
-
依托单位:
HEMATOPOIESIS TRAINING GRANT
-
批准号:6380337
-
项目类别:
-
资助金额:$18.56万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
Hematopoiesis training grant
-
批准号:7075386
-
项目类别:
-
资助金额:$30.81万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
VAV ANTISENSE ODN--A NOVEL THERAPEUTIC FOR HUMAN LEUKEMIAS
-
批准号:6103323
-
项目类别:
-
资助金额:$21.6万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
Hematopoiesis training grant
-
批准号:6802117
-
项目类别:
-
资助金额:$22.39万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
Hematopoiesis training grant
-
批准号:7629896
-
项目类别:
-
资助金额:$15.29万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
Hematopoiesis training grant
-
批准号:7260422
-
项目类别:
-
资助金额:$31.81万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
Hematopoiesis training grant
-
批准号:7475619
-
项目类别:
-
资助金额:$24.86万
-
财政年份:1999
-
负责人:Alan M Gewirtz
-
依托单位:
海外基金